Carlo Rizzuto is a Venture Partner with Versant Ventures and focuses on biotech investing and company building. He also serves as CEO of Highline Therapeutics, Versant’s New York City-based incubator.
Carlo joined Versant from Novartis Pharmaceuticals where he led global product development teams in the advancement of innovative pipeline products. He previously held the position of Associate Principal with McKinsey & Company advising U.S. and European clients in the pharmaceutical, payor, and provider sectors. Prior to joining McKinsey, Carlo helped found engeneOS, a Boston-based biotech startup.
Carlo received a PhD in Virology from Harvard University and a BA in Biology from the University of Virginia.
I was a management consultant in a former life, and was trained in that role to always have three arguments to support any conclusion. But having spent the last six months... Read more »
From Our Partners · Special Report
Advice for funding and future transformational opportunities
Sponsored · Whitepaper
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
PRA Health SciencesSponsored · Whitepaper
CMC in Drug Development and Life Cycle Management
PRA Health Sciences© 2007-2022, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.